9 Meters Biopharma (NMTR) Stock Price, News & Analysis

Company Overview

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 315,915 shs
• Market Capitalization: $1.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NMTR Stock Analysis - Frequently Asked Questions

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.26.

When did 9 Meters Biopharma's stock split?

Shares of 9 Meters Biopharma reverse split before market open on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 9 Meters Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 9 Meters Biopharma investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), SNDL (SNDL), NIO (NIO), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 3/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NMTR
• CIK: 1551986
• Web: www.9meters.com
• Phone: (919) 275-1933
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-43,770,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -584.97%
• Return on Assets: -159.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.59
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 14,336,000
• Free Float: 13,992,000
• Market Cap: $1.04 million
• Optionable: No Data
• Beta: 1.36